Phosphodiesterase-5 inhibitors in treatment of pulmonary artery hypertension
Pulmonary arterial hypertension is a rare serious disease resulting in a progressive increase in pulmonary arterial resistance, leading to fatal right heart failure and death [16, 17, 31]. Pulmonary hypertension can occur either in isolation (idiopathic pulmonary arterial hypertension) or related to other systemic pathologies (for example, systemic sclerosis or scleroderma) [18]. Pulmonary hypertension is characterized by an increase of average blood pressure in the pulmonary artery (Ppa) above 25 mm hg at rest [4, 5].